VTGN Insider Trading

Insider Ownership Percentage: 1.29%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Vistagen Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Vistagen Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Vistagen Therapeutics Share Price & Price History

Current Price: $2.92
Price Change: +0.30 (1.20%)
As of 01/17/2025 05:00 PM ET

This chart shows the closing price history over time for VTGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$2.92Closing price on 01/20/25:

Vistagen Therapeutics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Vistagen Therapeutics (NASDAQ:VTGN)

78.39% of Vistagen Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VTGN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$232kbought$2.59MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$10M$0$10MTotal InflowsTotal Outflows
Vistagen Therapeutics logo
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Read More on Vistagen Therapeutics

Today's Range

Now: $2.92
Low: $2.85
High: $3.10

50 Day Range

MA: $2.73
Low: $2.25
High: $3.34

52 Week Range

Now: $2.92
Low: $2.22
High: $5.74

Volume

107,706 shs

Average Volume

363,829 shs

Market Capitalization

$81.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Who are the company insiders with the largest holdings of Vistagen Therapeutics?

Vistagen Therapeutics' top insider shareholders include:
  1. Commodore Capital Lp (Major Shareholder)
Learn More about top insider investors at Vistagen Therapeutics.